Vivos Therapeutics (VVOS) Invested Capital (2019 - 2026)

Vivos Therapeutics' (VVOS) quarterly Invested Capital came in at $7.3 million in Q1 2026, up 4244.64% on a QoQ basis from $168000.0 in Q4 2025.

Vivos Therapeutics (VVOS) Invested Capital (2019 - 2026) Analysis & Trends

Vivos Therapeutics (VVOS) has 5 years of Invested Capital data on file, last reported at $7.3 million in Q1 2026.

On a quarterly basis, Invested Capital changed N/A year-over-year to $7.3 million in Q1 2026; TTM through Mar 2026 was $8.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $168000.0, changed N/A from the prior year.
Invested Capital for Q1 2026 stood at $7.3 million, up from $168000.0 in the prior quarter.
Over the last five years, Invested Capital for VVOS reached as high as $7.3 million in Q1 2026 and fell as low as $157000.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Abbott Laboratories	183.80 Bn	176.50 Bn	6.27 Bn	4.41 Bn
2	Stryker	128.84 Bn	125.96 Bn	3.81 Bn	499.00 Mn
3	Medtronic	108.59 Bn	99.37 Bn	6.41 Bn	1.79 Bn
4	Boston Scientific	68.51 Bn	67.06 Bn	3.61 Bn	41.00 Mn
5	Edwards Lifesciences	48.18 Bn	44.51 Bn	1.29 Bn	-
6	Dexcom	28.40 Bn	27.28 Bn	750.30 Mn	-
7	GE HealthCare Technologies	28.16 Bn	25.88 Bn	1.98 Bn	7.00 Mn
8	Smith & Nephew	26.89 Bn	26.31 Bn	-	15.00 Mn
9	Koninklijke Philips	24.66 Bn	21.54 Bn	2.07 Bn	1.41 Bn
10	Vivos Therapeutics	5.79 Mn	3.68 Mn	3.06 Mn	7.30 Mn

Download Data